TCP
ISEE

Tourbillon Capital Partners’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Tourbillon Capital Partners’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,360,202
Closed -$6.57M – 79
2016
Q4 		$6.57M Buy
+1,360,202
New +$40.4M 0.13% 59

Other funds holding ISEE

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Tourbillon Capital Partners's ISEE Position: Q1 2017 in Review

Tourbillon Capital Partners sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q1 2017, closing a stake of 1,360,202 shares — an estimated $6.57M sold.

Tourbillon Capital Partners first reported a position in ISEE in Q4 2016 and held it in 1 quarter. The position peaked at $6.57M in Q4 2016. 100 funds tracked by Wall St. Rank hold ISEE as of Q1 2017.

  • Tourbillon Capital Partners reported no remaining IVERIC bio, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • Tourbillon Capital Partners sold 1,360,202 IVERIC bio, Inc. Common Stock shares in Q1 2017, an estimated $6.57M.
  • Tourbillon Capital Partners first reported a position in IVERIC bio, Inc. Common Stock in Q4 2016 and held it in 1 quarter.
  • Tourbillon Capital Partners's IVERIC bio, Inc. Common Stock position peaked at $6.57M in Q4 2016.
  • 100 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q1 2017.

Based on Tourbillon Capital Partners's 13F filing for Q1 2017, filed 15 May 2017.